Search Orphan Drug Designations and Approvals
-
| Generic Name: | Melphalan | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Alkeran For Injection | ||||||||||||||||
| Date Designated: | 02/24/1992 | ||||||||||||||||
| Orphan Designation: | Treatment of patients with multiple myeloma for whom oral therapy is inappropriate. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park, North Carolina 27709 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Melphalan |
|---|---|---|
| Trade Name: | Alkeran For Injection | |
| Marketing Approval Date: | 11/18/1992 | |
| Approved Labeled Indication: | For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate. | |
| Exclusivity End Date: | 11/18/1999 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







